Astellas Pharma Inc. sued OSI Pharmaceuticals Inc. over its rejection of a $3.5 billion hostile takeover bid aimed at helping the Japanese company expand in cancer treatments.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.